Today IFM Therapeutics announced the acquisition of IFM Due, one of its subsidiaries, by Novartis. Back in Sept 2019, IFM granted Novartis the right to...
At a time when biotech is still counting its losses as a thaw gradually sets in after the long market winter, pharma has been on a...
Some are saying that mRNA medicines—mRNA vaccines and mRNA therapeutics alike—will open a golden era of medicine. And the enthusiasm is catching. Following...
The convergence of polymer chemistry, materials science, biology, and computation lets scientists assess a plethora of polymer delivery options. The post...
Accent Therapeutics raised $75 million in Series C funding from three Big Pharma companies and other investors to test its first two precision oncology...
“This study reflects transdisciplinary efforts to link aging and circadian biology in human-derived tissues, which is an understudied area of biology.”...
A once-promising brand faces a likely liquidation and an ugly end.
November 9, 2023, SEOUL, Republic of Korea and BANDUNG, Indonesia — The International Vaccine Institute (IVI), an international organization with a mission...
In September, Invivyd dosed its first patient in the Phase III CANOPY pivotal trial (NCT06039449), designed to assess VYD222’s ability to protect against...
“The proposed NOD/SCID model, with its accelerated ovarian aging, holds particular value as it will enable the observation of ovarian changes within...
As BioNTech continues to beef up its oncology pipeline, it’s once again turning to a Chinese partner. The German biotech is putting down $55 million...
A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators....
Months after chopping about a quarter of its US workforce, Sangamo Therapeutics is back with another round of layoffs to tighten its belt. As the Californian...
PHILADELPHIA—(Nov. 1, 2023)—The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy...
AstraZeneca is beefing up its cell and gene therapy potential by collaborating with and investing in French biotech Cellectis, starting out with a $25...
Recent preclinical results indicate novel next-generation vaccine candidates developed at Cleveland Clinic protect against multiple strains of influenza...
Executives at gene therapy startup Lexeo Therapeutics will likely make the 25-minute trek from their headquarters to Nasdaq’s trading floor later this...
Fyodor Urnov, PhD, is a pioneer in the field of genome editing and one of the scientists most invested in expanding the availability and utility of...
Christian Antoni Montai Health has kept most of its business under wraps since emerging from stealth last December. But this week the startup hired its...
Prime Medicine, a biotech company developing a new class of gene editors that promises to make nearly any change to any gene, said the first tests...
A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been...
Verve Therapeutics is planning to begin an in-human base editing trial in the US in patients with heterozygous familial hypercholesterolemia (HeFH) after...
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and Beijing Chaoyang Hospital have developed a new “pseudo...
MADRID — When Daiichi Sankyo scientists pushed forward with antibody-drug conjugate research nearly a decade ago, the program had a lot of naysayers,...
Merck has chosen not to pick up two preclinical antibody-drug conjugates from its partner Sichuan Kelun-Biotech, the Chinese drugmaker disclosed Monday. The...
Orlando, FL – 19 October 2023 – The Syngap Research Fund (SRF) will host Uniting for Progress — its fifth annual conference on SYNGAP1 research...
The first AI-designed drugs have ended with disappointment. Over the last year-plus, the first handful of molecules created by artificial intelligence...
Laronde and Senda Biosciences, two biotech startups founded by Flagship Pioneering that collectively raised more than $750 million, are merging to form...
Michelle Teng, CEO and co-founder of Etcembly and co-founder of SynaptixBio, spoke with Inside Precision Medicine's senior editor Helen Albert about her...
By Benjamin Boettner Credit: Wyss Institute at Harvard University By Benjamin Boettner (Boston) — The lung is one of the tissues most sensitive to radiation...